The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 12, 2025
Filed:
Jun. 22, 2018
Systimmune, Inc., Redmond, WA (US);
Sichuan Baili Pharmaceutical Co. Ltd., Chengdu, CN;
Yi Zhu, Chengdu, CN;
Ole Olsen, Everett, WA (US);
Dong Xia, Redmond, WA (US);
David Jellyman, Duvall, WA (US);
Katrina Bykova, Seattle, WA (US);
Anne-Marie K. Rousseau, Seattle, WA (US);
Bill Brady, Bothell, WA (US);
Blair Renshaw, Renton, WA (US);
Brian Kovacevich, Snohomish, WA (US);
Yu Liang, Redmond, WA (US);
Camilla Wang, Sammamish, WA (US);
Zeren Gao, Redmond, WA (US);
SYSTIMMUNE, INC., Redmond, WA (US);
Abstract
The application provides guidance and navigation control (GNC) proteins. In one embodiment, the GNC protein Comprises a T-cell binding moiety and a cancer-targeting moiety, wherein the T-cell binding moiety has a binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof, and wherein the cancer targeting moiety has a binding specificity to a cancer cell receptor.